• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Positive INBRX-106 Phase 2 Data And Narrower Losses At Inhibrx Biosciences (INBX) Have Changed Its Investment Story

    Simply Wall St·05/25/2026 13:25:30
    Listen to the news
    • In May 2026, Inhibrx Biosciences reported a first-quarter net loss of US$33.44 million, narrower than a year earlier, and released positive interim Phase 2 data from its HexAgon trial of INBRX-106 plus pembrolizumab in first-line PD-L1 positive metastatic or unresectable recurrent head and neck squamous cell carcinoma.
    • The interim data showed a higher confirmed objective response rate and the emergence of complete responses with the INBRX-106 combination, underscoring the potential significance of OX40 costimulation in boosting checkpoint inhibitor activity.
    • We will now examine how the early efficacy signal from INBRX-106 in head and neck cancer informs Inhibrx Biosciences' broader investment narrative.

    This technology could replace computers: discover 28 stocks that are working to make quantum computing a reality.

    What Is Inhibrx Biosciences' Investment Narrative?

    To own Inhibrx Biosciences, you have to believe its OX40 and sdAb platforms can translate compelling science into clinically meaningful, partnerable assets before the balance sheet tightens further. The HexAgon interim readout strengthens the near term story by providing a clear efficacy signal for INBRX-106 on top of pembrolizumab, and it potentially elevates the planned Phase 3 start and upcoming PFS data into more meaningful catalysts than they looked a few months ago. At the same time, the company remains a loss making, early commercial stage biotech with limited revenue, negative equity and ongoing cash burn, so execution risk around larger, later stage trials and any eventual commercial build remains high. The stock’s sharp one year move suggests expectations have already shifted, even before analysts formally update their models for this data.

    However, one key risk around funding those bigger trials is easy to underestimate. The analysis detailed in our Inhibrx Biosciences valuation report hints at an inflated share price compared to its estimated value.

    Exploring Other Perspectives

    INBX 1-Year Stock Price Chart
    INBX 1-Year Stock Price Chart
    The Simply Wall St Community’s single fair value estimate of US$277.50 contrasts sharply with recent price swings, while the strengthened INBRX-106 signal and Phase 3 ambitions only increase the stakes around funding and execution.

    Explore another fair value estimate on Inhibrx Biosciences - why the stock might be worth just $277.50!

    The Verdict Is Yours

    Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Searching For A Fresh Perspective?

    Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.